"Highlands Oncology is dedicated to providing the highest quality of innovative cancer care delivered with compassion and precision. With locations in Springdale, Fayetteville, and Rogers, we provide Northwest Arkansas with comprehensive cancer care."

During the past decade, Highlands Oncology Group conducted 102 clinical trials. In the 10-year time frame, 102 clinical trials started and 120 clinical trials were completed, i.e. on average, 117.6% percent of trials that started reached the finish line to date. In the past 5 years, 29 clinical trials started and 52 clinical trials were completed. i.e. 179.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Highlands Oncology Group" #1 sponsor was "Novartis Pharmaceuticals" with 70 trials, followed by "Eli Lilly and Company" with 25 trials sponsored, "Pfizer" with 20 trials sponsored, "National Cancer Institute (NCI)" with 18 trials sponsored and "SWOG Cancer Research Network" with 18 trials sponsored. Other sponsors include 114 different institutions and companies that sponsored additional 73 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Highlands Oncology Group" #1 collaborator was "National Cancer Institute (NCI)" with 25 trials as a collaborator, "Merck Sharp & Dohme LLC" with 7 trials as a collaborator, "NCIC Clinical Trials Group" with 5 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator and "SWOG Cancer Research Network" with 4 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "Highlands Oncology Group" are "Breast Cancer" (29 trials), "Non-Small Cell Lung Cancer" (14 trials), "Metastatic Breast Cancer" (12 trials), "Melanoma" (10 trials) and "Breast Neoplasms" (9 trials). Many other conditions were trialed in "Highlands Oncology Group" in a lesser frequency.

Most popular intervention types in "Highlands Oncology Group" are "Drug" (239 trials), "Other" (31 trials), "Biological" (25 trials), "Procedure" (9 trials) and "Radiation" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (37 trials), "Paclitaxel" (20 trials), "Carboplatin" (18 trials), "Gemcitabine" (14 trials) and "Fulvestrant" (13 trials). Other intervention names were less common.

The vast majority of trials in "Highlands Oncology Group" are 204 trials for "All" genders, 49 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "Highlands Oncology Group". undefined are not yet recruiting, 35 are recruiting, 42 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 135 completed trials in Highlands Oncology Group, undefined suspended trials, and 37 terminated clinical trials to date.

Out of the total trials that were conducted in Highlands Oncology Group, 61 "Phase 1" clinical trials were conducted, 114 "Phase 2" clinical trials and 96 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 4 trials that are defined as “Not Applicable".

Highlands Oncology Group has several departments that took part in Clinical trials: "Highlands Oncology Group - Springdale" - 16 trials